20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
2025 Paris Marathon
Join what is now one of the biggest marathons in the world and get the chance to discover one of the world’s greatest cities while supporting Cure Parkinson’s! Race day will see you pound the pavements of the French capital’s most famous avenues and plazas....
Raid Alpine 2022: Team take on the Alps
Setting off on 4 July, 22 dedicated challenge cyclists took on the Raid Alpine route, cycling 770 kilometres through some of the most feared climbs, to raise funds for Cure Parkinson’s and support the charity’s search for a cure.
Dr Simon Stott appointed to Director of Research at Cure Parkinson’s
21 June 2022 Cure Parkinson’s is pleased to announce that Dr Simon Stott, current Deputy Director of Research at Cure Parkinson’s, has been promoted to the role of Director of Research. Simon will lead on fostering promising new lines of research, and continue to promote…
The influence of diabetes on Parkinson’s progression
In recent research funded by Cure Parkinson’s, scientists have provided the strongest evidence to date that diabetes can affect the progression of Parkinson’s.
Inhibikase makes a case for c-Abl
Research has suggested that in some cases of Parkinson’s a protein called c-Abl tyrosine kinase is abnormally over-active and this contributes to nerve cell inflammation and eventual cell death. The biotech company, Inhibikase, has been developing a drug which dampens down abnormal c-Abl protein.